Study identifies first drug therapy for sleep apnea
Researchers at UC San Diego found tirzepatide, a diabetes drug, promising for treating sleep apnea. The study on 469 participants worldwide showed reduced breathing interruptions, weight loss, and improved heart health. Tirzepatide may offer a new OSA treatment option.
Read original article
A study led by researchers at the University of California San Diego School of Medicine has identified tirzepatide, a drug used to manage type 2 diabetes, as a potential first drug therapy for obstructive sleep apnea (OSA). The study, published in the New England Journal of Medicine, involved 469 participants with obesity and moderate-to-severe OSA from nine countries. Results showed that tirzepatide significantly reduced breathing interruptions during sleep, with some participants potentially not needing continuous positive airway pressure (CPAP) therapy. The drug also improved cardiovascular risk factors and body weight. Dr. Atul Malhotra, the lead author, highlighted the drug's potential to offer a more accessible alternative for OSA treatment, especially for individuals who struggle with existing therapies. The study suggests that combining CPAP therapy with weight loss could optimize cardiometabolic risk management. Further research will focus on examining the long-term effects of tirzepatide. Funding for the study was provided by Eli Lilly and Company, with Dr. Malhotra serving as a consultant to the company.
Related
OpenPipe Mixture of Agents: Outperform GPT-4 at 1/25th the Cost
OpenPipe's cost-effective agent mixture surpasses GPT-4, promising advanced language processing at a fraction of the cost. This innovation could disrupt the market with its high-performance, affordable language solutions.
Walking to combat back pain
A study by Macquarie University's Spinal Pain Research Group reveals regular walking reduces low back pain recurrence. Combining walking with education sessions proves effective and cost-efficient in preventing back pain long-term.
The Opaque Industry Inflating Prices for Prescription Drugs
Pharmacy Benefit Managers (PBMs) like CVS Health, Cigna, and UnitedHealth Group are criticized for increasing prescription drug costs in the US. Despite claims of cost reduction, PBMs allegedly steer towards expensive drugs, charge high markups, and prioritize financial gains over patients. Lawmakers are scrutinizing their practices for potential price inflation and anticompetitive behavior.
Top FDA official overrules staff to approve gene therapy that failed trial
The FDA approved Elevidys gene therapy for Duchenne muscular dystrophy, despite controversy over failed trials. Dr. Peter Marks led the decision, facing criticism for prioritizing emotional arguments over scientific evidence.
Next-generation psychedelics: should new agents skip the trip?
Companies are investing in next-generation psychedelics to enhance mental health treatment, focusing on reducing psychoactive effects while maintaining therapeutic benefits. Despite expanding interest and investments, questions persist about efficacy and cost-effectiveness.
5 comments Key multiplicity-controlled secondary end points included the percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure.
(honestly, I could more easily imagine an exercise pill)
Yes I know it says it right below it.
Related
OpenPipe Mixture of Agents: Outperform GPT-4 at 1/25th the Cost
OpenPipe's cost-effective agent mixture surpasses GPT-4, promising advanced language processing at a fraction of the cost. This innovation could disrupt the market with its high-performance, affordable language solutions.
Walking to combat back pain
A study by Macquarie University's Spinal Pain Research Group reveals regular walking reduces low back pain recurrence. Combining walking with education sessions proves effective and cost-efficient in preventing back pain long-term.
The Opaque Industry Inflating Prices for Prescription Drugs
Pharmacy Benefit Managers (PBMs) like CVS Health, Cigna, and UnitedHealth Group are criticized for increasing prescription drug costs in the US. Despite claims of cost reduction, PBMs allegedly steer towards expensive drugs, charge high markups, and prioritize financial gains over patients. Lawmakers are scrutinizing their practices for potential price inflation and anticompetitive behavior.
Top FDA official overrules staff to approve gene therapy that failed trial
The FDA approved Elevidys gene therapy for Duchenne muscular dystrophy, despite controversy over failed trials. Dr. Peter Marks led the decision, facing criticism for prioritizing emotional arguments over scientific evidence.
Next-generation psychedelics: should new agents skip the trip?
Companies are investing in next-generation psychedelics to enhance mental health treatment, focusing on reducing psychoactive effects while maintaining therapeutic benefits. Despite expanding interest and investments, questions persist about efficacy and cost-effectiveness.